Persistence and Use of Ixekizumab in Patients with Psoriatic Arthritis in Real-World Practice in Spain. The PRO-STIP Study

ConclusionsPsA patients treated with IXE in a real-world setting show high treatment persistence through 104  weeks and improvements in disease activity after treatment initiation. This suggests that IXE could be an effective treatment for patients with PsA.Retrospectively registeredDate of registration: 25th May 2021.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research